key: cord-1037428-5j083pxo
authors: Ahmed, Hanad; Badran, Abdul; Tamburrini, Alessandro; Kattach, Hassan; Veres, Lukacs; Alzetani, Aiman
title: Endobronchial Valves in the Management of Persistent Air Leak in COVID-19
date: 2021-09-04
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2021.08.011
sha: f4409c2a5e733b75d815eedf0af33b87186ad0a0
doc_id: 1037428
cord_uid: 5j083pxo

Pneumothorax and persistent air leak (PAL) are documented complications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Patients that fall in this category are often poor candidates for invasive thoracic surgical intervention. Endobronchial valves offer an effective and less invasive treatment option and can successfully treat PAL and support the weaning of patients with SARS-CoV-2 pneumonia off ventilation.

Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) leads to a range of disease presentations, from fever and cough to life-threatening embolic events and Acute Respiratory Distress Syndrome (ARDS) 1 . Some authors have highlighted spontaneous pneumothoraces and persistent air leaks (PAL) as a potential complication 2,3,4 . Despite conservative efforts some patients require thoracic surgical intervention 4 which must be balanced against their premorbid status, and ability to tolerate surgery, especially in the setting of single-lung ventilation. 5 We herein report the use of endobronchial valves (EBV) in the definitive management of persistent pneumothorax and PAL in the setting of SARS-CoV-2 infection, avoiding invasive thoracic surgical intervention.

A 49-year-old male was transferred to our centre following a 2-month history of bilateral SARS-CoV-2 pneumonitis treated with dexamethasone and tocilizumab and a 3-week history of PAL causing significant respiratory failure. Past medical history included a recent diagnosis of sarcoidosis.

On arrival, the patient received ventilation supported through a tracheostomy on a slow weaning regimen. However, he was still on fraction of inspired oxygen (FiO2) of 70% with a Positive end-expiratory pressure (PEEP) of 6cm H20, achieving tidal volumes of 554ml, oxygen saturations of 98% and a PaCO2 of 8.9kpa. Two right sided chest drains were in-situ with a large continuous air leak. Nasopharyngeal swabs were negative for SARS-CoV-2 on admission to our unit, although the diagnosis was confirmed earlier in the course of admission.

Other relevant laboratory findings included a white blood cell count of 4.7x10*9/L, C-reactive protein 328 mg/, haemoglobin 85g/L and the isolation of haemophilus influenza from sputum, methicillin sensitive staphylococcus aureus from the tracheostomy site and Escherichia coli from the pleural fluid. The patient was initially started on Meropenem before de-escalating to EBV are therefore an attractive and less invasive alternative in the treatment of PAL, with a one-way valve collapsing the culprit site by allowing air exit whilst preventing entry. The optimal timing of EBV insertion must be carefully considered and balanced against the risk of procedure failure. The thick, copious secretions in COVID-19 lung pose a risk of EBV occlusion. Medical management of the infection as well as drainage of the air leak are therefore crucial first steps in managing these patients before EBV can be considered.

EBV may have a potential role in the treatment of PAL and can support the weaning of patients with COVID-19 off ventilation without the need for invasive intervention. To the best of our knowledge this is the first case report demonstrating the use of a Chartis catheter and Zephyr valves in the definitive management of PAL and pneumothorax caused by a bronchopleural fistula in a patient with COVID-19. We hope that this case report offers some insight into the alternative interventions available for this patient group, avoiding the need for surgery.

J o u r n a l P r e -p r o o f

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Mediastinal Emphysema, Giant Bulla, and Pneumothorax Developed during the Course of COVID-19 Pneumonia

High incidence and mortality of pneumothorax in critically Ill patients with COVID-19. Heart Lung

Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia